EYPT vs. TXG, AEHR, ALNT, TRNS, LAB, CTKB, SENS, QSI, FEIM, and MASS
Should you be buying Eyepoint Pharmaceuticals stock or one of its competitors? The main competitors of Eyepoint Pharmaceuticals include 10x Genomics (TXG), Aehr Test Systems (AEHR), Allient (ALNT), Transcat (TRNS), Standard BioTools (LAB), Cytek Biosciences (CTKB), Senseonics (SENS), Quantum-Si (QSI), Frequency Electronics (FEIM), and 908 Devices (MASS). These companies are all part of the "measuring and control equipment" industry.
Eyepoint Pharmaceuticals vs. Its Competitors
Eyepoint Pharmaceuticals (NASDAQ:EYPT) and 10x Genomics (NASDAQ:TXG) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, risk, institutional ownership, valuation, media sentiment, dividends, analyst recommendations and earnings.
In the previous week, 10x Genomics had 7 more articles in the media than Eyepoint Pharmaceuticals. MarketBeat recorded 9 mentions for 10x Genomics and 2 mentions for Eyepoint Pharmaceuticals. 10x Genomics' average media sentiment score of 0.77 beat Eyepoint Pharmaceuticals' score of 0.37 indicating that 10x Genomics is being referred to more favorably in the news media.
Eyepoint Pharmaceuticals currently has a consensus target price of $26.86, indicating a potential upside of 95.45%. 10x Genomics has a consensus target price of $13.65, indicating a potential upside of 7.12%. Given Eyepoint Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Eyepoint Pharmaceuticals is more favorable than 10x Genomics.
Eyepoint Pharmaceuticals has higher earnings, but lower revenue than 10x Genomics. 10x Genomics is trading at a lower price-to-earnings ratio than Eyepoint Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
10x Genomics has a net margin of -13.13% compared to Eyepoint Pharmaceuticals' net margin of -337.93%. 10x Genomics' return on equity of -12.88% beat Eyepoint Pharmaceuticals' return on equity.
Eyepoint Pharmaceuticals has a beta of 1.95, indicating that its share price is 95% more volatile than the S&P 500. Comparatively, 10x Genomics has a beta of 2.05, indicating that its share price is 105% more volatile than the S&P 500.
99.4% of Eyepoint Pharmaceuticals shares are held by institutional investors. Comparatively, 84.7% of 10x Genomics shares are held by institutional investors. 4.5% of Eyepoint Pharmaceuticals shares are held by company insiders. Comparatively, 10.0% of 10x Genomics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Summary
10x Genomics beats Eyepoint Pharmaceuticals on 9 of the 16 factors compared between the two stocks.
Get Eyepoint Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for EYPT and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding EYPT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Eyepoint Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:EYPT) was last updated on 10/6/2025 by MarketBeat.com Staff
